Hillsborough, NJ, United States of America

Chandra Vemavarapu

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Chandra Vemavarapu

Introduction: Chandra Vemavarapu, a pioneering inventor located in Hillsborough, NJ, has made significant contributions to the pharmaceutical industry. With a keen focus on thromboembolic disorders, her innovative journey has led to the development of unique formulations that harness the power of apixaban, a crucial anticoagulant.

Latest Patents: Vemavarapu holds a patent for apixaban formulations. The patent describes compositions comprising crystalline apixaban particles having a diameter equal to or less than 89 micrometers, combined with a pharmaceutically acceptable carrier. These formulations are significantly bioequivalent and provide essential options for the treatment and prophylaxis of thromboembolic disorders.

Career Highlights: Throughout her career, Chandra Vemavarapu has worked with renowned companies in the pharmaceutical sector, including Bristol-Myers Squibb Company and Pfizer Corporation. Her expertise in drug formulation and development has been instrumental in driving innovative solutions for complex health challenges.

Collaborations: Vemavarapu has collaborated with notable professionals in her field, including Jatin M Patel and Charles Frost. These partnerships have helped in the refinement and advancement of her patent work, leading to impactful developments in therapeutic applications.

Conclusion: Chandra Vemavarapu's inventive spirit continues to impact the pharmaceutical landscape. With her groundbreaking patent on apixaban formulations and a career marked by significant collaborations and contributions, she stands as a testament to the importance of innovation in medicine. Her work not only addresses current medical needs but also sets the stage for future advancements in the treatment of thromboembolic disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…